GLP-1 maintenance after goal weight: why not go compounded?

You set a number when you started. This month, the scale showed it. The refill reminder arrived the same week, with no question about whether the dose should change. A few days later, an email offered a compounded version for less. If you are working out GLP-1 maintenance after goal weight, that email raises a fair question. Why not take the cheaper one now that the hard part is done?

The person in this piece is a composite and is not a real patient. You lost the weight over many months on a GLP-1 prescribed through an app. You feel better than you have in a long time. You also have no plan for what comes next, because nobody has offered you one. This piece answers the compounded question plainly. GoodLife Health's own answer to maintenance is a clinician who manages the long haul and tests before the dose is decided, whether or not you end up building your plan with us.

What happens after the scale shows the number?

The first months on a GLP-1 have a shape. The dose starts low and rises in steps. Your appetite quiets. The weight comes off, sometimes faster than you expected. Each refill arrives on schedule. For months, the plan is simply the next step up.

The months after goal weight have no shape at all. Nobody has told you whether the dose should stay where it is, come down slowly or stop. Those are three different decisions with three different costs. You have heard friends describe the weight returning after they stopped. You have no way to know whether their stories describe your body. That uncertainty is the hardest part of this stage. It is also the part the refill reminder never mentions.

Meanwhile, the bill keeps arriving. If you pay a self-pay price for a branded pen or vial, maintenance can feel like paying full price every month for a result you already have. The compounded offer speaks to that feeling directly. You did the work. Maintenance sounds like coasting. A cheaper vial of what is sold as the same molecule looks like the sensible choice for a household that does not like to waste money.

There is something else the email leaves out. Think back to how this started. Perhaps it was a questionnaire and one short video visit. If no one drew blood before your first dose, there is no baseline to compare against now. Nobody knows what your fasting insulin was before the weight came off or where your Hemoglobin A1c (HbA1c) sits today. Nobody can say whether your cholesterol markers moved with the scale. Without those numbers, the dose decision in front of you is a guess, whoever makes it.

You may also feel that you already have a prescriber and that switching sounds like work. That instinct is reasonable. A prescriber who has been there since the first dose knows part of your story. The useful question is what that prescriber is set up to do now that the goal has shifted from losing weight to holding on to your health.

You are not looking for permission to spend more. You want to know whether the cheaper option costs something that never appears on the invoice. The rest of this piece answers that with dates and sources.

What is really being decided at goal weight?

At goal weight, the main question is the dose. Holding it, lowering it and tapering it are clinical decisions. Each one should rest on your own numbers and on how your body has responded so far. We do not know which path is right for you. Neither does an email offering a cheaper vial.

The trials behind these medicines report averages. In STEP 1, adults on semaglutide 2.4 mg lost an average of 14.9% of their body weight over 68 weeks. In SURMOUNT-1, the figure was 20.9% on tirzepatide 15 mg over 72 weeks. An average describes a population. It cannot tell you what your own body will do when the dose changes. That answer comes from your own markers, read over time.

Who decides the dose matters as much as the dose itself. Our white paper on how GLP-1 telehealth companies make money sets out the three ways a company gets paid. Some earn a margin on the medicine. Some charge a low membership and bill insurance. Some charge one flat fee and send the medicine to a pharmacy at the pharmacy's own price. The model decides what the company is rewarded for, whatever the character of its clinicians.

Under the first model, the platform's revenue grows with your prescription. The guide to Aligned Medicine describes a low advertised membership with the margin in the medication and an upcharge as the dose titrates up. During weight loss, that structure and your goal point the same way. At goal weight, they can part. The clinically right move may be a steady dose, a lower one or a slow taper. A business paid on the dose earns less from two of those three.

Now consider the cheaper vial itself. Compounded semaglutide and tirzepatide were legal during the shortage that began in 2022. Federal law lets pharmacies copy a medicine while it is on the FDA's shortage list. For roughly three years, many telehealth companies sold compounded copies. Many people used them legally and did nothing wrong.

Then supply caught up. The FDA declared the tirzepatide shortage resolved in December 2024 and the semaglutide shortage resolved on February 21, 2025. The last enforcement grace periods closed in spring 2025, with the final deadline for outsourcing facilities on May 22, 2025. In 2026, the FDA proposed permanently excluding both medicines from the list outsourcing facilities may compound in bulk. Both manufacturers have sued companies selling compounded versions. The FDA sets out its position on its page about unapproved GLP-1 drugs used for weight loss.

What remains is narrow. A pharmacy may still compound a GLP-1 for one specific patient with a documented clinical need the branded product cannot meet, such as an allergy to an ingredient. A compounded copy is mixed by a pharmacy from raw ingredients. The FDA has not reviewed it for safety or effectiveness. The clinician who prescribes it carries that responsibility on their own license.

Maintenance changes the weight of these facts because it is the long haul. The cheaper vial asks you to build that long haul on a supply that now rests on an exception rather than a rule. That is why GoodLife Health prescribes branded, FDA-approved GLP-1 only. The choice has a cost. Our members pay the branded price, which is higher.

The branded side looks different in 2026. Both manufacturers publish their own self-pay prices. As of September 2026, NovoCare lists Wegovy pens at $199 a month for the first two fills and $349 a month after. The $199 price is an introductory offer for new patients through December 2026. The Wegovy pill starts at $149 a month at lower doses. LillyDirect lists Zepbound vials at $299 to $449 a month depending on dose. A patient can read those prices before a prescription is written. Branded medication at a published price is one direction the field has taken. Testing before treating is the other. Maintenance is where the two meet.

What does the membership do at goal weight and what does it cost?

GoodLife Health gives GLP-1 maintenance a clinician who manages the long haul. The membership tests first, prescribes branded medication to your pharmacy at that pharmacy's price and costs the same at every dose. It is clinician-led precision direct primary care for cardiometabolic optimization: diagnosis first, then treatment, then the long haul.

It starts with the eligibility check, the intake and the checkout. A clinician then reviews your case and decides whether to accept you into care. Not everyone is accepted.

Once you are in care, the first panel gives you the baseline nobody drew. The membership includes four cardiometabolic lab panels a year, one every 90 days. Every result is in your hands. Fasting Insulin and Hemoglobin A1c (HbA1c) are read together. Apolipoprotein B (ApoB) and the Lipid Panel, Standard are tracked beside them. Those markers show your clinician how your metabolic health looks at the weight you reached. They are drawn every 90 days, so a change appears as a trend in your record.

The clinician reviews the dose you are on now and decides with you whether to hold it, lower it or taper it. If you are on a compounded product today, the clinician reviews your current dose and decides with you how to move to a branded medication, if a GLP-1 is still indicated. No path is promised in advance.

Medication is prescribed only when it is clinically indicated, to the pharmacy you choose, at that pharmacy's own price. GoodLife Health sets nothing, sees nothing and takes nothing on it. The GLP-1 options are branded and FDA-approved: Wegovy, Zepbound, Mounjaro and Ozempic. Zepbound and Mounjaro are the same molecule, tirzepatide. Oral options are prescribed when they are indicated.

The fee is $299 a month whatever the medication and whatever the dose. Over a year, the membership is $3,588. A lower dose costs the membership nothing. A taper costs it nothing either. As the guide to Aligned Medicine puts it, if your labs improve and your clinician can taper you, nothing in the business resists it.

Between panels, you can message the care team and book video visits. If your weight starts to return, you message the clinician who set the plan. That clinician reads the change against your markers and adjusts the plan with you.

That leaves the question patients raise at this stage. Why pay a membership when the drug is the expensive part? The membership pays for the person deciding how much of the drug you take and for the numbers that decision rests on. The fee does not move with the dose, so that person has no stake in the answer. You pay the pharmacy its own price for the medication and nothing more.

GoodLife Health sits between the $20,000-a-year concierge practice and the $99-a-month compounded app. We say so openly. The membership costs more than that app does. The case for it rests on what each price pays for and on who benefits when your dose changes.

There are also things the membership does not do. It does not guarantee that your weight will hold. It does not promise that insurance will cover a medication. Prior authorization is the pharmacy's process, so we do not run it or promise its outcome. The membership pairs with your insurance for catastrophic coverage and does not replace it. It prescribes no compounded GLP-1 at any dose.

What should you do this week?

Start with the prescriber you have. Ask three questions. What blood work should come before a maintenance dose is set? How does your company get paid when my dose changes? What is the plan if my weight starts to return? A prescriber who has thought about maintenance can answer all three. If the answers are vague, you have still learned something useful.

Then look up the manufacturer's self-pay price for your medication on NovoCare or LillyDirect. Write the date beside it, because these prices are revised. If you are on a compounded product, ask which pharmacy makes it and on what basis it is compounded now that both shortages are over. You are entitled to that answer.

Finally, ask for a copy of any blood work you have had since you started. If there is none, you know where a maintenance plan has to begin. That first panel is worth having wherever you get it.

Who this is not for

This membership is not for you if the lowest monthly cost decides the question. If you want a compounded vial at the smallest price and no blood work, the $99 app is built for that and we are not. It is not for you if you want a promise that your weight will stay where it is, because nobody can honestly make one. It is not for you if you want the membership to replace your insurance or to win a prior authorization. It is not for anyone who lives outside the United States.

It may be for you if you reached goal weight and want the next decision made on your numbers by a clinician with no stake in the dose. The membership is $299 a month. At sign-up, $598 is held on your card for the first two months. It is a hold, charged only once a clinician accepts you into care. If the clinician cannot accept you, the hold is released and you are never charged. Once you are accepted, the first two months are charged and are non-refundable. After that, the membership runs month to month. Medication billed by a pharmacy follows that pharmacy's own return and refund policy. The fee buys a panel every 90 days, a clinician who stays and messaging with the care team between video visits. Medication is prescribed to your pharmacy at that pharmacy's price. GoodLife Health takes nothing on it. In return, you get the workup a quick visit never produced, your markers followed over time and no repeat of the eight-minute visit. The model tests first and treats second. It sells neither the drug nor the dose. The reason to start now is your own timing. The dose decision is in front of you this month. It is better made on a first panel than left to the next refill.

Related Reading

• How GLP-1 Telehealth Companies Make Money: A Plain-Language Whitepaper
• Aligned Medicine: How Zero-Markup Healthcare Actually Works
• The GLP-1 dose-escalation trap
• Cardiometabolic optimization: the definitive guide

References

1. NovoCare Pharmacy — Wegovy self-pay pricing (Novo Nordisk). 2026. www.novocare.com/pharmacy/wegovy.html
2. Zepbound Self Pay Journey Program — LillyDirect vial pricing (Eli Lilly). 2026. zepbound.lilly.com/savings
3. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (U.S. Food and Drug Administration). 2025. www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
4. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). 2021. pubmed.ncbi.nlm.nih.gov/33567185/
5. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). 2022. pubmed.ncbi.nlm.nih.gov/35658024/